Therapy

Health
HeathCare
Therapy
TradersPro Alerts

Trillium Therapeutics Inc. (TRIL) Buy Target $4.59 Sell Target $5.88

Trade Setup Buy Target $4.59 Sell Target $5.88 Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic […]

Read More
Health
HeathCare
Therapy
TradersPro Alerts

Karyopharm Therapeutics Inc. (KPTI) Buy Target $19.59 Sell Target $23.41

Trade Setup Buy Target $19.59 Sell Target $23.41 Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit […]

Read More
Health
HeathCare
Therapy
TradersPro Alerts

Can-Fite BioPharma Ltd. (CANF) Buy Target $2.22 Sell Target $2.92

Trade Setup Buy Target $2.22 Sell Target $2.92 Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company’s lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis.

Read More
Health
HeathCare
Therapy
TradersPro Alerts

XOMA Corporation (XOMA) Buy Target $24.74 Sell Target $26.31

Trade Setup Buy Target $24.74 Sell Target $26.31 XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, […]

Read More
One Hot Stock
Therapy

Genprex, Inc. (GNPX) – Buy Target – $1.85 or better

Buy Target – $1.85 or better Sell Target – TradersPro Sell Signal Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which […]

Read More

FREE TRAINING - TRADERSPRO PRESENTS: Retire In 18 Months With $2.4 Million?

Join Us Now
X